查看購物車
  • English
封面
市場調查報告書
商品編碼
1912742

一次性無菌採血管市場按類型、材質、應用和最終用戶分類－2026-2032年全球預測

Disposable Sterile Blood Collection Tube Market by Type, Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年一次性無菌採血管市場價值為 4.6027 億美元，預計到 2026 年將成長至 4.8863 億美元，年複合成長率為 8.41%，到 2032 年將達到 8.1027 億美元。

關鍵市場統計數據
基準年 2025 4.6027億美元
預計年份：2026年 4.8863億美元
預測年份 2032 8.1027億美元
複合年成長率 (%) 8.41%

一次性無菌採血管概述：簡要介紹材料、設計演變以及檢測準確性和安全性的臨床重要性

一次性無菌採血管是臨床診斷和檢體管理的重要組成部分，有助於確保檢測流程的準確性和病人安全。材料科學、無菌生產通訊協定和人體工學設計的最新進展提高了單次使用採血管的可靠性和易用性。這些採血降低了交叉感染的風險，簡化了採血流程，並可與自動化分析儀和條碼系統整合，從而最大限度地減少可能影響診斷準確性的分析前變異。

材料創新、無菌製造技術的進步以及診斷自動化如何重塑產品設計、採購重點和供應商優勢

技術、監管和營運等多方面因素正在推動一次性無菌採血管市場格局發生顯著變化。首先，材料創新正在加速從傳統玻璃向先進塑膠的過渡，先進塑膠具有更優異的抗衝擊性，降低了生物危害風險，並實現了可擴展的自動化生產。同時，無菌生產流程也日趨完善，採用檢驗的環境控制措施和一次性生產組件，最大限度地減少顆粒物和微生物污染。

評估近期美國關稅對營運和採購的影響，這些關稅已經改變了供應鏈風險狀況和籌資策略。

美國近期關稅政策的變化對一次性無菌採血管的供應鏈動態產生了切實的影響，波及原料成本、籌資策略和庫存管理。針對原料聚合物、特殊添加劑或成品一次性醫用產品的關稅措施可能會增加依賴國際採購的製造商的到岸成本。為此，許多供應商和醫療採購商正在重新評估其供應商組合，以降低關稅波動帶來的風險。具體而言，他們正尋求供應商位置多元化，並擴大區域製造地的使用。

基於全面細分的洞察，將管道類型、材質、最終用戶環境和應用需求與採購和產品開發槓桿聯繫起來

了解市場區隔對於使產品開發、行銷和分銷策略與最終用戶需求保持一致至關重要。按類型分類，我們分析真空採血管和非真空採血管，這決定了它們與真空採血系統的兼容性，並影響高通量採血操作人員的使用體驗。按材質，我們考察玻璃管和塑膠管，這一區別為決策提供了依據，有助於評估檢體完整性、破損風險以及對特定分析方法的適用性。依最終使用者分類，我們分析血庫、診斷檢查室和醫院的市場，重點在於採購週期、樣本量需求和法律規範的差異。按應用分類，我們分析生物化學檢驗、血液學、分子診斷和血清學檢測的市場，重點關注添加劑配方、抗凝血劑和採血管設計對檢測性能和後續處理的影響。

美洲、歐洲、中東和非洲以及亞太地區的區域特徵如何影響製造地的選擇、監管策略和市場進入方式

區域趨勢在全球醫療保健系統的製造地、監管策略和需求促進因素方面發揮關鍵作用。在美洲，採購重點在於大規模機構買家、集中式分銷網路以及逐步採用的自動化採血流程。這些趨勢有利於能夠提供規模經濟、合規文件和綜合服務協議的供應商。同時，歐洲、中東和非洲地區的管理體制和採購機制各不相同。先進的檢查室基礎設施與資源有限的環境並存，靈活的產品系列和多樣化的包裝規格有助於市場滲透。相較之下，亞太地區都市區的診斷現代化進程迅速推進，同時本地製造能力也在不斷增強，這就要求供應商在滿足全球品質標準、區域成本競爭力以及符合當地監管要求之間取得平衡。

決定一次性無菌採血管領域供應商競爭優勢的關鍵因素包括品質系統、整合能力和服務能力。

一次性無菌採血管的競爭優勢主要體現在生產品質、法規遵循和與檢查室工作流程的整合等。領先的製造商將投入大量資金打造檢驗的無菌生產環境、實施嚴格的批次檢測通訊協定，並對原料供應商進行資格認證，以確保產品性能的穩定性。同時，那些能夠將設備生產與貼標、序列化和物流等配套服務相結合的公司，能夠為那些傾向於選擇能夠減輕管理負擔的承包解決方案的機構買家提供更有價值的提案。

為製造商和負責人提供切實可行的策略性舉措，以增強韌性、加速產品差異化並更好地與臨床和採購工作流程保持一致。

產業領導者應採取切實可行的措施，重點在於增強供應鏈韌性、深化產品差異化以及與臨床工作流程更加緊密地銜接。首先，企業應實現採購多元化，考慮區域性生產和策略聯盟，以降低關稅波動和運輸中斷帶來的風險，同時透過嚴格的供應商篩選和庫存最佳化來確保供應的連續性。其次，需要增加對材料科學和設計創新的投入，以提高樣品穩定性、降低破損率並確保自動化相容性。此外，應優先考慮生物相容性和批次可追溯性的清晰文件記錄，以滿足日益嚴格的監管要求。

我們採用了一種嚴謹的混合調查方法，結合了對關鍵相關人員的訪談、技術文獻綜合和供應鏈分析，以獲得可靠的見解。

本調查方法結合了定性和定量技術，以確保基於一手和二手證據得出切實可行的見解。一手研究包括對實驗室主任、採購經理、品質保證經理和生產主管進行結構化訪談，以了解營運重點、採購週期以及與一次性無菌採血管相關的關鍵挑戰。我們獲得了關於分析設備相容性要求、特定檢測方法添加劑偏好以及物流和可追溯性服務期望的第一手資訊。

本文全面分析了製造、監管和供應鏈選擇如何共同決定血液採集裝置的臨床效用和採購結果。

總而言之，一次性無菌採血管面臨臨床需求、生產精度和供應鏈複雜性三者交會的挑戰。隨著檢查室現代化和自動化程度的不斷提高，材料選擇、管材設計和添加劑配方變得日益重要。關稅變化和貿易摩擦凸顯了採購多元化和區域化生產策略的必要性，而按類型、材料、最終用戶和應用進行細分則為精準的產品定位提供了明確的機會。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：一次性無菌採血管市場（按類型分類）

  • 真空管
  • 非真空管

第9章：一次性無菌採血管市場（依材料分類）

  • 玻璃管
  • 塑膠管

第10章：按應用分類的一次性無菌採血管市場

  • 生物化學
  • 血液學
  • 分子診斷
  • 血清學

第11章：依最終用戶分類的一次性無菌採血管市場

  • 血庫
  • 診斷檢查室
  • 醫院

第12章：按地區分類的一次性無菌採血管市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 一次性無菌採血管市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：各國一次性無菌採血管市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國一次性無菌採血管市場

第16章 中國一次性無菌採血管市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Becton, Dickinson and Company
  • Boen Healthcare Co., Ltd.
  • Corning Incorporated
  • Greiner Bio-One International GmbH
  • Hill-Rom Holdings, Inc.
  • Nipro Corporation
  • Sarstedt AG & Co. KG
  • Sekisui Medical Co., Ltd.
  • SunTech Medical, Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB13A6B

The Disposable Sterile Blood Collection Tube Market was valued at USD 460.27 million in 2025 and is projected to grow to USD 488.63 million in 2026, with a CAGR of 8.41%, reaching USD 810.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 460.27 million
Estimated Year [2026] USD 488.63 million
Forecast Year [2032] USD 810.27 million
CAGR (%) 8.41%

A concise orientation to disposable sterile blood collection tubes highlighting materials, design evolution, and clinical importance for laboratory accuracy and safety

Disposable sterile blood collection tubes serve as fundamental components in clinical diagnostics and specimen management, supporting accurate laboratory workflows and patient safety. Over recent years, advancements in materials science, sterile manufacturing protocols, and design ergonomics have elevated the reliability and usability of single-use collection devices. These tubes reduce cross-contamination risk, streamline phlebotomy procedures, and integrate with automated analyzers and barcode systems, thereby minimizing pre-analytical variability that can compromise diagnostic accuracy.

Incorporating disposability as a design principle responds to heightened infection control standards and regulatory focus on sterile medical devices. Moreover, the rising complexity of diagnostic panels has driven demand for a broader range of tube types and additives tailored to specific assays and storage conditions. Consequently, procurement teams, laboratory directors, and clinical supply chain managers increasingly evaluate blood collection tubes not only on cost-per-unit but also on compatibility with laboratory instrumentation, ease of use, and traceability features. This introduction frames the subsequent analysis by situating disposable sterile blood collection tubes at the nexus of clinical quality, operational efficiency, and regulatory compliance.

How material innovation, sterile manufacturing advances, and diagnostic automation are reshaping product design, procurement priorities, and supplier advantage

The landscape surrounding disposable sterile blood collection tubes has shifted markedly due to converging technological, regulatory, and operational forces. First, material innovation has accelerated movement away from traditional glass toward advanced plastics that offer improved break-resistance and lower biohazard risk while enabling scalable, automated production. At the same time, sterile manufacturing processes have become more sophisticated, incorporating validated environmental controls and single-use production components to minimize particulate and microbial contamination.

Parallel to material and process advancements, the clinical environment has driven demand for tubes compatible with high-throughput analyzers and multiplex molecular platforms. Laboratories are standardizing on tubes that support both pre-analytical automation and sample stability for downstream molecular diagnostics. Regulatory emphasis on device traceability and biocompatibility has led manufacturers to incorporate unique identifiers, tamper-evident seals, and standardized additive formulations. As a result, procurement decisions now weigh interoperability and lifecycle risk alongside unit price, and suppliers that offer integrated solutions-combining devices, labeling, and data capture-are positioned to capture preference in institutional buying cycles.

Assessing the operational and sourcing consequences of recent United States tariff actions that have altered supply chain risk profiles and procurement tactics

Recent tariff developments in the United States have had a tangible effect on the supply chain dynamics for disposable sterile blood collection tubes, influencing input costs, sourcing strategies, and inventory management. Tariff measures targeting raw polymers, specialty additives, or finished medical disposables can increase landed costs for manufacturers that rely on international sourcing. In response, many suppliers and healthcare purchasers have reassessed supplier portfolios to mitigate exposure to tariff volatility, seeking diversification of vendor locations and increased use of regional manufacturing hubs.

Consequently, organizations have adopted a mix of tactical and strategic responses. Tactically, procurement teams have adjusted lead times and expanded buffer inventories to absorb potential cost changes and shipment delays. Strategically, original equipment manufacturers and private-label producers have evaluated nearshoring or onshoring opportunities to reduce dependence on tariff-affected supply lines and to secure faster turnaround for critical orders. At the same time, some producers have invested in process efficiencies and value engineering to offset tariff-driven cost inflation while preserving product performance and regulatory compliance. Overall, tariffs have reinforced the importance of supply chain transparency and flexible sourcing as core components of resilience planning for diagnostic consumables.

Comprehensive segmentation-driven insights linking tube type, material, end-user environment, and application needs to procurement and product development levers

Understanding segmentation is essential to align product development, marketing, and distribution strategies with end-user needs. Based on Type, market is studied across Evacuated Tube and Non-Evacuated Tube, which defines compatibility with vacuum-based phlebotomy systems and affects ease of use for high-volume phlebotomists. Based on Material, market is studied across Glass Tube and Plastic Tube, and this distinction informs decisions about sample integrity, breakage risk, and suitability for certain analytic methods. Based on End User, market is studied across Blood Bank, Diagnostic Laboratory, and Hospital, which highlights differing procurement cycles, volume requirements, and regulatory oversight across institutional settings. Based on Application, market is studied across Biochemistry, Hematology, Molecular Diagnostics, and Serology, which underscores how additive formulations, anticoagulants, and tube design influence assay performance and downstream processing.

Taken together, these segmentation lenses reveal distinct pathways for product differentiation. Evacuated tubes that pair with automation and barcoding workflows typically appeal to high-throughput diagnostic laboratories, while non-evacuated tubes may retain strength in point-of-care or small-clinic settings that prioritize simplicity and cost. Plastic tubes offer durability and safety benefits for hospitals and blood banks, whereas certain biochemical assays continue to prefer glass for compatibility with specific analyte stability profiles. For molecular diagnostics and specialized serology testing, validated additive formulations and strict lot-to-lot consistency become decisive selection criteria, prompting suppliers to emphasize quality systems and traceability in their value propositions.

How distinct regional forces across the Americas, Europe Middle East and Africa, and Asia-Pacific dictate manufacturing choices, regulatory strategy, and go-to-market approaches

Regional dynamics play a crucial role in shaping manufacturing footprints, regulatory strategies, and demand drivers across global healthcare systems. In the Americas, procurement emphasizes large institutional buyers, centralized distribution networks, and gradual adoption of automated phlebotomy workflows; these patterns favor suppliers that can deliver scale, compliance documentation, and integrated service agreements. Meanwhile, Europe, Middle East & Africa exhibits diverse regulatory regimes and procurement mechanisms; pockets of advanced laboratory infrastructure coexist with resource-constrained settings, so flexible product portfolios and variable pack sizes support market penetration. In contrast, Asia-Pacific presents a mix of rapid diagnostic modernization in urban centers and growing local manufacturing capacity, prompting suppliers to balance global quality standards with regional cost competitiveness and localized regulatory registrations.

These regional distinctions influence decisions from facility placement to regulatory dossiers and sales strategy. For example, manufacturers targeting hospital systems in the Americas may prioritize contracting capabilities and after-sales logistics, whereas success in Europe, Middle East & Africa often requires tailored regulatory pathways and partnerships to reach decentralized public health procurement. In Asia-Pacific, partnering with local distributors and aligning product specifications to regional laboratory practices accelerate adoption, particularly where in-country production reduces tariff exposure and shortens lead times. Ultimately, a regionally nuanced approach yields better alignment with buyer expectations and resiliency against supply chain disruptions.

Key supplier characteristics that determine competitive advantage in the disposable sterile blood collection tube arena including quality systems, integration, and service capabilities

Competitive dynamics in disposable sterile blood collection tubes center on manufacturing quality, regulatory compliance, and the ability to integrate with laboratory workflows. Leading manufacturers invest heavily in validated sterile production environments, stringent lot-testing protocols, and supplier qualification for raw materials to ensure consistent product performance. In parallel, firms that combine device production with complementary services-such as labeling, serialization, and logistics-create stronger value propositions for institutional purchasers who prefer turnkey solutions that reduce administrative burden.

Moreover, strategic differentiation increasingly relies on demonstrable compatibility with automation and digital tracking systems, as well as the capacity to support specialized applications like molecular diagnostics. Companies that maintain broad distribution networks and strong relationships with hospital procurement teams gain advantages in contract negotiations and rollout speed. At the same time, emerging players often focus on niche segments-such as cost-optimized plastic tube lines for resource-limited settings or premium formulations tailored to advanced serology-to carve out defensible positions. Overall, competition rewards firms that can combine product reliability, regulatory clarity, and service depth while remaining responsive to evolving clinical requirements.

Practical strategic moves for manufacturers and buyers to build resilience, accelerate product differentiation, and align offerings more closely with clinical and procurement workflows

Actionable steps for industry leaders should focus on strengthening supply chain resilience, deepening product differentiation, and forging closer ties to clinical workflows. First, companies should diversify sourcing and consider regional manufacturing or strategic partnerships to reduce exposure to tariff swings and shipping disruptions, while simultaneously implementing rigorous supplier qualification and inventory optimization to maintain continuity. Second, invest in material science and design innovations that improve sample stability, reduce breakage, and ensure compatibility with automation; prioritize clear documentation of biocompatibility and lot traceability to meet tightening regulatory expectations.

Third, align commercial models to end-user workflows by offering integrated solutions-packaging, labeling, and data capture services-that simplify procurement and reduce the burden on hospital supply chains. Fourth, expand clinical engagement through field validation studies and clinician education to demonstrate how tube selection affects assay outcomes and laboratory efficiency. Finally, deploy targeted pricing and contract structures that reflect total cost of ownership rather than unit price alone, thereby enabling longer-term partnerships that support volume stability and continuous improvement initiatives.

A rigorous mixed-methods research approach combining primary stakeholder interviews, technical literature synthesis, and supply chain analysis to ensure credible insights

The research approach combined qualitative and quantitative methods to ensure robust, actionable findings grounded in primary and secondary evidence. Primary engagement included structured interviews with laboratory directors, procurement managers, quality assurance leads, and manufacturing executives to capture operational priorities, procurement cycles, and key pain points related to disposable sterile blood collection tubes. These conversations offered direct insight into compatibility requirements with analyzers, additive preferences for specific assays, and service expectations around logistics and traceability.

Secondary analysis synthesized regulatory guidance documents, manufacturing standards, and peer-reviewed literature on specimen handling and pre-analytical variables to validate technical assertions. Supply chain mapping and trade policy reviews provided context for sourcing risks and tariff impacts. Data triangulation across multiple sources supported consistent interpretation, while sensitivity checks ensured that conclusions emphasized operational and strategic implications rather than speculative projections. Throughout the process, adherence to ethical interviewing protocols and data verification strengthened the integrity of the research outputs.

Concluding synthesis of how manufacturing, regulatory, and supply chain choices converge to determine clinical utility and procurement outcomes for blood collection devices

In summary, disposable sterile blood collection tubes sit at an intersection of clinical necessity, manufacturing precision, and supply chain complexity. Material choices, tube design, and additive formulations now carry greater weight as laboratories modernize and automation becomes more prevalent. Tariff changes and trade frictions have underscored the need for diversified sourcing and regional manufacturing strategies, while segmentation across type, material, end user, and application reveals clear opportunities for targeted product positioning.

Companies that excel will pair high-quality manufacturing controls with services that reduce administrative burden for buyers and demonstrate measurable compatibility with diagnostic workflows. By proactively addressing regulatory documentation, supply chain transparency, and clinical validation, manufacturers and purchasers can enhance resilience and improve patient safety outcomes. The conclusion is straightforward: deliberate investments in quality systems, strategic sourcing, and workflow integration will deliver the operational and clinical benefits that healthcare institutions increasingly demand.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Disposable Sterile Blood Collection Tube Market, by Type

  • 8.1. Evacuated Tube
  • 8.2. Non-Evacuated Tube

9. Disposable Sterile Blood Collection Tube Market, by Material

  • 9.1. Glass Tube
  • 9.2. Plastic Tube

10. Disposable Sterile Blood Collection Tube Market, by Application

  • 10.1. Biochemistry
  • 10.2. Hematology
  • 10.3. Molecular Diagnostics
  • 10.4. Serology

11. Disposable Sterile Blood Collection Tube Market, by End User

  • 11.1. Blood Bank
  • 11.2. Diagnostic Laboratory
  • 11.3. Hospital

12. Disposable Sterile Blood Collection Tube Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Disposable Sterile Blood Collection Tube Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Disposable Sterile Blood Collection Tube Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Disposable Sterile Blood Collection Tube Market

16. China Disposable Sterile Blood Collection Tube Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Becton, Dickinson and Company
  • 17.6. Boen Healthcare Co., Ltd.
  • 17.7. Corning Incorporated
  • 17.8. Greiner Bio-One International GmbH
  • 17.9. Hill-Rom Holdings, Inc.
  • 17.10. Nipro Corporation
  • 17.11. Sarstedt AG & Co. KG
  • 17.12. Sekisui Medical Co., Ltd.
  • 17.13. SunTech Medical, Inc.
  • 17.14. Terumo Corporation
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY EVACUATED TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY NON-EVACUATED TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GLASS TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY PLASTIC TUBE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BIOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY BLOOD BANK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. GCC DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. G7 DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NATO DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA DISPOSABLE STERILE BLOOD COLLECTION TUBE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)